[The research progress on de-escalation and optimization strategies for the treatment of early-stage breast cancer].

With the advancement of precision medicine, the treatment of early-stage breast cancer is gradually moving toward standardized individualization. While ensuring therapeutic efficacy, increasing attention is being given to patients' quality of life. In recent years, as clinical research data on targeted therapies for HER2-positive breast cancer, CDK4/6 inhibitors for hormone receptor-positive breast cancer, and immune checkpoint inhibitors for triple-negative breast cancer have accumulated, the treatment of early-stage breast cancer has become more precise and personalized. Furthermore, the growing body of clinical research on breast-conserving surgery, axillary preservation, and even the omission of primary tumor resection has significantly improved patients' quality of life. These more effective drugs and advanced technologies provide the foundation for de-escalation treatment strategies in early-stage breast cancer, driving the development of a more refined, patient-centered treatment approach.